Spatial Domain (Tier 1)
1,701-1,750 of 2,070
Download spatial tables
Spatial Domain (Tier 1)
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__87_C7,10 | Lung | Primary cancer | 3,319 | Tumor/Malignant | 33.0% | 0.92 | 0.24 |
| NSCLC_38242124__IMC__87_C7,11 | Lung | Primary cancer | 3,593 | Tumor/Malignant | 81.0% | 1.00 | 0.02 |
| NSCLC_38242124__IMC__87_C7,12 | Lung | Primary cancer | 2,821 | Tumor/Malignant | 57.4% | 1.00 | 0.04 |
| NSCLC_38242124__IMC__87_C7,13 | Lung | Primary cancer | 2,047 | Tumor/Malignant | 64.7% | 0.94 | 0.19 |
| NSCLC_38242124__IMC__87_C7,14 | Lung | Primary cancer | 287 | Stromal | 86.8% | 0.62 | 0.58 |
| NSCLC_38242124__IMC__87_C7,15 | Lung | Primary cancer | 31 | Other | 61.3% | 0.58 | 0.78 |
| NSCLC_38242124__IMC__87_C7,16 | Lung | Primary cancer | 1,929 | Tumor/Malignant | 66.7% | 0.97 | 0.08 |
| NSCLC_38242124__IMC__87_C7,17 | Lung | Primary cancer | 1,224 | Other | 33.2% | 0.35 | 1.00 |
| NSCLC_38242124__IMC__87_C7,2 | Lung | Primary cancer | 2,400 | Stromal | 43.3% | 0.89 | 0.28 |
| NSCLC_38242124__IMC__87_C7,4 | Lung | Primary cancer | 3,448 | Tumor/Malignant | 59.3% | 0.96 | 0.18 |
| NSCLC_38242124__IMC__87_C7,5 | Lung | Primary cancer | 2,372 | Immune | 27.3% | 0.39 | 0.95 |
| NSCLC_38242124__IMC__87_C7,6 | Lung | Primary cancer | 2,851 | Tumor/Malignant | 46.2% | 0.94 | 0.22 |
| NSCLC_38242124__IMC__87_C7,7 | Lung | Primary cancer | 3,276 | Immune | 29.3% | 0.75 | 0.52 |
| NSCLC_38242124__IMC__87_C7,8 | Lung | Primary cancer | 2,571 | Tumor/Malignant | 33.8% | 0.94 | 0.18 |
| NSCLC_38242124__IMC__87_C7,9 | Lung | Primary cancer | 3,011 | Stromal | 33.0% | 0.89 | 0.35 |
| NSCLC_38242124__IMC__87_C8,1 | Lung | Primary cancer | 2,861 | Tumor/Malignant | 44.9% | 0.91 | 0.31 |
| NSCLC_38242124__IMC__87_C8,10 | Lung | Primary cancer | 3,523 | Immune | 41.1% | 0.92 | 0.23 |
| NSCLC_38242124__IMC__87_C8,11 | Lung | Primary cancer | 4,114 | Stromal | 32.6% | 0.78 | 0.55 |
| NSCLC_38242124__IMC__87_C8,12 | Lung | Primary cancer | 4,101 | Tumor/Malignant | 32.2% | 0.56 | 0.71 |
| NSCLC_38242124__IMC__87_C8,13 | Lung | Primary cancer | 1,447 | Other | 36.3% | 0.40 | 0.99 |
| NSCLC_38242124__IMC__87_C8,14 | Lung | Primary cancer | 3,518 | Tumor/Malignant | 78.5% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__87_C8,15 | Lung | Primary cancer | 2,755 | Immune | 25.6% | 0.34 | 1.00 |
| NSCLC_38242124__IMC__87_C8,16 | Lung | Primary cancer | 888 | Stromal | 29.7% | 0.39 | 0.95 |
| NSCLC_38242124__IMC__87_C8,17 | Lung | Primary cancer | 734 | Other | 33.9% | 0.34 | 0.95 |
| NSCLC_38242124__IMC__87_C8,2 | Lung | Primary cancer | 2,429 | Tumor/Malignant | 48.7% | 0.89 | 0.35 |
| NSCLC_38242124__IMC__87_C8,3 | Lung | Primary cancer | 1,975 | Immune | 35.2% | 0.33 | 0.99 |
| NSCLC_38242124__IMC__87_C8,4 | Lung | Primary cancer | 2,879 | Tumor/Malignant | 34.3% | 0.56 | 0.78 |
| NSCLC_38242124__IMC__87_C8,5 | Lung | Primary cancer | 2,271 | Stromal | 52.7% | 0.92 | 0.25 |
| NSCLC_38242124__IMC__87_C8,6 | Lung | Primary cancer | 3,518 | Tumor/Malignant | 42.7% | 0.95 | 0.22 |
| NSCLC_38242124__IMC__87_C8,7 | Lung | Primary cancer | 3,142 | Tumor/Malignant | 62.2% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__87_C8,8 | Lung | Primary cancer | 2,268 | Immune | 33.1% | 0.29 | 1.01 |
| NSCLC_38242124__IMC__87_C8,9 | Lung | Primary cancer | 2,466 | Tumor/Malignant | 29.0% | 0.93 | 0.22 |
| NSCLC_38242124__IMC__88_A1,1 | Lung | Primary cancer | 3,920 | Tumor/Malignant | 59.6% | 0.91 | 0.29 |
| NSCLC_38242124__IMC__88_A1,10 | Lung | Primary cancer | 2,846 | Tumor/Malignant | 76.9% | 0.99 | 0.06 |
| NSCLC_38242124__IMC__88_A1,11 | Lung | Primary cancer | 2,755 | Tumor/Malignant | 46.0% | 0.96 | 0.12 |
| NSCLC_38242124__IMC__88_A1,12 | Lung | Primary cancer | 3,172 | Tumor/Malignant | 45.6% | 0.74 | 0.58 |
| NSCLC_38242124__IMC__88_A1,13 | Lung | Primary cancer | 2,621 | Tumor/Malignant | 66.1% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__88_A1,14 | Lung | Primary cancer | 1,569 | Tumor/Malignant | 44.6% | 0.95 | 0.22 |
| NSCLC_38242124__IMC__88_A1,15 | Lung | Primary cancer | 2,801 | Tumor/Malignant | 39.3% | 0.93 | 0.24 |
| NSCLC_38242124__IMC__88_A1,16 | Lung | Primary cancer | 2,975 | Tumor/Malignant | 65.1% | 0.98 | 0.10 |
| NSCLC_38242124__IMC__88_A1,2 | Lung | Primary cancer | 26 | Tumor/Malignant | 100.0% | 0.96 | 0.02 |
| NSCLC_38242124__IMC__88_A1,3 | Lung | Primary cancer | 1,919 | Immune | 27.8% | 0.86 | 0.39 |
| NSCLC_38242124__IMC__88_A1,4 | Lung | Primary cancer | 86 | Tumor/Malignant | 87.2% | 0.97 | 0.09 |
| NSCLC_38242124__IMC__88_A1,5 | Lung | Primary cancer | 410 | Stromal | 45.9% | 0.89 | 0.32 |
| NSCLC_38242124__IMC__88_A1,6 | Lung | Primary cancer | 2,608 | Tumor/Malignant | 67.0% | 0.95 | 0.15 |
| NSCLC_38242124__IMC__88_A1,7 | Lung | Primary cancer | 3,686 | Tumor/Malignant | 62.1% | 0.97 | 0.13 |
| NSCLC_38242124__IMC__88_A1,8 | Lung | Primary cancer | 1,662 | Stromal | 37.5% | 0.93 | 0.21 |
| NSCLC_38242124__IMC__88_A1,9 | Lung | Primary cancer | 4,187 | Tumor/Malignant | 33.2% | 0.76 | 0.54 |
| NSCLC_38242124__IMC__88_A2,1 | Lung | Primary cancer | 4,162 | Tumor/Malignant | 49.6% | 0.91 | 0.28 |
| NSCLC_38242124__IMC__88_A2,10 | Lung | Primary cancer | 2,723 | Tumor/Malignant | 35.7% | 0.93 | 0.18 |